1167415-61-3

Basic information

• Product Name: 2-[(1-methylethyl)oxy]-5-[3-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1,2,4-oxadiazol-5-yl]benzonitrile hydrochloride
• Synonyms: 2-[(1-methylethyl)oxy]-5-[3-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1,2,4-oxadiazol-5-yl]benzonitrile hydrochloride
• CAS NO: 1167415-61-3
• Molecular Weight: 410.903
• Mol File: 1167415-61-3.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2-[(1-methylethyl)oxy]-5-[3-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1,2,4-oxadiazol-5-yl]benzonitrile hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[(1-methylethyl)oxy]-5-[3-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1,2,4-oxadiazol-5-yl]benzonitrile hydrochloride(1167415-61-3)
• EPA Substance Registry System: 2-[(1-methylethyl)oxy]-5-[3-(2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)-1,2,4-oxadiazol-5-yl]benzonitrile hydrochloride(1167415-61-3)

Safety Data

• Hazardous Substances Data: 1167415-61-3(Hazardous Substances Data)

Upstream product

• 175714-94-0 1,1-dimethylethyl 7-[(hydroxyamino)(imino)methyl]-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 
• 1072948-37-8 3-cyano-4-[(1-methylethyl)oxy]benzoyl chloride 
• 264264-28-0 1,1-dimethylethyl-7-{[(trifluoromethyl)sulfonyl]oxy}-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 
• 149354-02-9 1,1-dimethylethyl 7-cyano-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 
• 258273-31-3 3-cyano-4-isopropoxybenzoic acid 
• 1167416-30-9 1,1-dimethylethyl 7-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate 

Downstream Products

• 1167416-38-7 ethyl 4-[7-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]butanoate 
• 1167416-39-8 ethyl 4-(7-{5-[4-[(1-methylethyl)oxy]-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl}-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)butanoate 
• 1167415-66-8 [7-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]acetic acid 
• 1167417-00-6 4-(7-(5-(3-cyano-4-isopropoxyphenyl)-1,2,4-oxadiazol-3-yl)-4,5-dihydro-1H-benzo[d]azepin-3(2H)-yl)butanoic acid 
• 1258855-42-3 4-[7-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]butanoic acid sodium salt 
• 1258855-70-7 2-[7-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-N-((2S)-2-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}propyl)acetamide 
• 1258855-71-8 [7-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]acetic acid mono-trifluoroacetate 
• 1258855-77-4 2-[7-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-N-((1R)-2-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}-1-methylethyl)acetamide 
• 1258855-79-6 2-[7-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-N-((1S)-2-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}-1-methylethyl)acetamide 
• 1258855-85-4 5-(3-{3-[2-(3-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}-1-azetidinyl)-2-oxoethyl]-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl}-1,2,4-oxadiazol-5-yl)-2-[(1-methylethyl)oxy]benzonitrile 
• 1258855-89-8 5-{3-[3-(2-aminoethyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-1,2,4-oxadiazol-5-yl}-2-[(1-methylethyl)oxy]benzonitrile monohydrochloride 
• 1258855-92-3 1,1-dimethylethyl {3-[7-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]propyl}carbamate 
• 1258855-91-2 5-{3-[3-(3-aminopropyl)-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl]-1,2,4-oxadiazol-5-yl}-2-[(1-methylethyl)oxy]benzonitrile monohydrochloride 
• 1258856-36-8 2-[7-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl]-2-methylpropanoic acid mono-trifluoroacetate 

Relevant articles and documents

Discovery of a brain-penetrant S1P3-sparing direct agonist of the S1P1 and S1P5 receptors efficacious at low oral dose

2-Amino-2-(4-octylphenethyl)propane-1,3-diol 1 (fingolimod, FTY720) has been recently marketed in the United States for the treatment of patients with remitting relapsing multiple sclerosis (RRMS). Its efficacy has been primarily linked to the agonism on

COMPOUNDS

The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.